Connect with us

Biotech

Hyloris biotech attracts new Flemish investors

Walloon companies have shown reactivity in the corona crisis, thanks to the structuring of the biopharma ecosystem and medical equipment. A sector that could take advantage of this delicate pass to support its development. The Liège-based biotech company Hyloris has raised $16.5 million (€15 million) to develop its reformulated medicines. The money will also be used to develop marketing strategies.

Published

on

This picture show two scientist.

Companies in the south of Belgium have shown great responsiveness in the coronavirus crisis. One of the explanations for this mobilization is the advanced structuring of the Walloon ecosystem of life sciences and medical equipment. A sector which, so far, is resisting well and could even take advantage of this delicate pass to consolidate its development.

Find out the latest breakthroughs in the biotech sector and read more about the round of financing recently closed by the Hyloris company with the Born2Invest mobile app. Be the first to find out the most important business news from around the world with our companion app, available for both Android and iOS devices.

Hyloris completed a financing round in the form of a convertible bond

Hyloris has just completed a nice round of financing in the midst of a coronavirus crisis. The Liège-based biotech company, created and managed by Flemish entrepreneur Stijn Van Rompay, has successfully completed a private fund-raising round of $16.5 million (€15 million) from a mix of new and existing investors, including Scorpiaux (the financial holding company of real estate entrepreneur Bart Versluys), the Liège-based investor Noshaq, Saffelberg Investments and Nomainvest (the holding company of the Noël family).

This raising consists of a convertible bond for the full amount and not a traditional capital increase. “The bond will be converted at the time of the next transaction, which could be, generally within 18 to 24 months, either a new capital raising, a sale or a pharmaceutical deal,” said Patrick Jeanmart, who has just joined the company as CFO.

The Lyon-based company has 12 product candidates in its portfolio

Hyloris develops pharmaceutical products with the objective of bringing high added value reformulated medicines to the market as quickly as possible. This strategy is based on American regulations applying to medicines for which the safety and efficacy of specific molecules have already been demonstrated. This procedure concerns, for example, medicines with new dosages or administered differently. It may also concern an extension of the indication.

SEE ALSO  How to evolve your business model as times change

The Liège-based company, which currently employs a dozen people, markets two products in the United States: one for the treatment of atrial fibrillation, developed in partnership with AltaThera, and the other is a non-opioid analgesic for the treatment of pain, co-owned with AFT Pharmaceuticals. Hyloris also has 12 product candidates at various stages of development in its portfolio.

The funds raised will be used in particular to finance development and marketing strategies, “with the long-term ambition of bringing considerably improved products to market,” explained Hyloris in its press release.

The Van Rompay family is known for its involvement in biopharmacy. It is notably at the origin of the creation, then resale, of Docpharma and Uteron Pharma. For his part, businessman Bart Versluys is not a newcomer to the sector either. Through Scorpiaux, he holds stakes in the American-Belgian diagnostics company MDxhealth, in Fagron and also in Mithra, companies that have also recently completed successfully financing rounds.

On Friday, April 24th, Mithra announced a financing agreement with LDA Capital guaranteeing it direct access to $54.3 million (€50 million). On April 27th, the Belgian-American biotech MDxHealth signaled its intention to raise $13.8 million (€12.7 million) via the issue of 20.1 million shares subscribed by MVM Partners.

__

(Featured image by FotoshopTofs via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in L’Echo, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Angelique Moss is a London-based entrepreneur, writer, and traveller. The world of business, finance, and technology, is her preferred cup of tea. She also writes about the developments and discussions on health, art, luxury and media. A top writer for several Medium publications, she has published hundreds of widely read articles on investing, stocks, global markets, cannabis, and technology for multiple platforms. She is also interested in culture, history, and social affairs.